Seaport Therapeutics (NASDAQ:SPTX) Director Robert Hombach Acquires 13,000 Shares of Stock

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Director Robert Hombach purchased 13,000 shares of the stock in a transaction dated Monday, June 22nd. The shares were acquired at an average price of $18.14 per share, for a total transaction of $235,820.00. Following the acquisition, the director directly owned 13,000 shares of the company’s stock, valued at $235,820. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Seaport Therapeutics Trading Up 1.8%

Seaport Therapeutics stock opened at $19.31 on Thursday. Seaport Therapeutics, Inc. has a twelve month low of $14.85 and a twelve month high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last posted its quarterly earnings results on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($10.64) by $0.30.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on SPTX. Zacks Research raised Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. Stifel Nicolaus began coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $30.00 price target for the company. BNP Paribas Exane downgraded shares of Seaport Therapeutics to a “market perform” rating in a research note on Tuesday, May 26th. Finally, UBS Group cut shares of Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $35.50.